


Catalog # 10-4475 IACS-010759

CAS# 1570496-34-2

5-[5-Methyl-1-[[3-(4-methylsulfonylpiperidin-1-yl)phenyl]methyl]-1,2,4-triazol-3-yl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethoxyphenyl]-3-[4-(trifluoromethox

oxadiazole



IACS-010759 is a potent ($IC_{50} = 1.1$ nM isolated mouse complex I) and selective inhibitor of complex I of the mitochondrial electron transport chain (OXPHOS). IACS-010759 displayed *in vivo* efficacy in glycolysis-deficient glioblastoma and AML models without cytotoxicity to normal cells. The lack of cytotoxicity to normal cells, as opposed to other complex I inhibitors, is attributed to its unique binding location on complex I.² Complex I inhibition by IACS-010759 causes an ROS-induced decrease in the endogenous PP2A inhibitor CIP2A leading to cell death.³ It has also displayed potential in various chemotherapy-resistant cancer cell lines.⁴⁻⁷

- 1) Molina et al. (2018), An inhibitor of oxidative phosphorylation exploits cancer vulnerability; Nature Med. 24 1036
- 2) Tsuji et al. (2020), IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism; J. Biol. Chem. **295** 7481
- 3) Cazzoli et al. (2023), Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition; Cell Rep. 42 112616
- 4) Gopal et al. (2019), A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma; Clin. Cancer Res. 25 6429
- 5) Stuani et al. (2021), Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia; J. Exp. Med. **218** e20200924
- 6) Evans et al. (2021), Oxidative Phosphorylation is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer, Cancer Res. 81 5572
- 7) Fuhr et al. (2022), CD52 and OXPHOS potential targets in ibrutinib-treated mantle cell lymphoma; Cell Death Discov. 8 505

PHYSICAL DATA

Molecular Weight:	562.57
Molecular Formula:	$C_{25}H_{25}F_3N_6O_4S$
Purity:	>98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (>25 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in
	DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462 www.focusbiomolecules.com